Three patients with polymyositis refractory to conventional steroid and immunosuppressive treatment, but responsive to cyclosporin A, are described. In a fourth patient cyclosporin A was used as a first line drug in combination with steroids in the treatment of life-threatening dermatomyositis. Cyclosporin A in the management of polymyositis/dermatomyositis requires formal assessment of its costs and benefits compared with conventional treatments.
No takes yet. Share an insight, caveat, or question.
Hey et al. (1970) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: